You can buy or sell IOVA and other stocks, options, ETFs, and crypto commission-free!
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. Read More The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
San Carlos, California
52 Week High
52 Week Low
Simply Wall StMar 5
Read This Before Selling Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares
We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or sell Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), you may well want to know whether insiders have been buying or selling. Do Insider Transactions Matter? It’s quite normal to see company insiders, such as board members, trading in company stock, fro...
Seeking AlphaFeb 27
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2018 Results - Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2018 Results Earnings Conference Call February 27, 2019 4:30 PM ET Company Participants Timothy Morris - CFO Maria Fardis - President & CEO Debora Barton - SVP, Clinical Science Conference Call Participants Mark Breidenbach - Oppenheimer Boris Peaker - Cohen George Zavoico - B. Riley FBR Operator Good afternoon, and welcome to the Iovance Biotherapeutics Fourth Quarter and Year End 2018 Financial Results Conference Call. All participants are in a list...
Expected May 9, After Hours